Compass Pathways Stock Earnings Reports

COMPASS Pathways reported material regulatory and commercial progress in Q1: they have positive Phase III data from two pivotal TRD studies (005 and 006), have started a rolling NDA submission to FDA, and were awarded a Commissioner’s National Priority Voucher (CNPV) which could materially accelerate final review once the NDA is complete. The company expects to complete submission after 26-week Part B data from study 006 (expected early Q3) and remains targetted to be launch-ready by year-end. They are proactively engaging the DEA regarding potential federal rescheduling and say ~90% of the U.S. population is in states that intend to reschedule promptly after federal action, reducing launch access risk. Commercially, COMPASS is scaling its commercial organization, has prepared psychedelic-specific CPT codes to support reimbursement for multi-hour monitoring, is engaging payers (with formal negotiations to follow once clinical profile is finalized), and plans to leverage existing interventional psychiatry clinics (the primary early delivery setting) for rollout. They also plan to pursue PTSD as the next indication and are engaged with VA programs. Financially, they completed financing/warrant actions and expect cash to fund operations well beyond launch into 2028. Key near-term milestones: submission completion after 006 Part B (early Q3), continued rolling module submissions, DEA engagement/rescheduling process, and commercial ramp toward a potential end-of-year launch.